Needham & Company Defending Seattle Genetics (SGEN); Remain Positively Inclined Towards B. vedotin and Current ADC Platform
Tweet Send to a Friend
Needham & Company reiterates a 'Buy' rating on Seattle Genetics (Nasdaq: SGEN).
Needham analyst says, "This morning, Seattle Genetics announced ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Needham analyst says, "This morning, Seattle Genetics announced ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
